Inpatient glycemic control guidelines during Covid pandemic

Dr Mohamad Ahangar Davoodi

Pediatric Endocrinologist Department of Pediatric, Arak University of Medical Sciences







Hyperglycemia management in hospitalized patients with COVID-19



Patients With Type 1 Diabetes Hospitalized for COVID-19 in the U.S.

Compared with patients without diabetes, T1DM was associated with a 21% higher absolute risk of ICU/MV and a 5% higher absolute risk of mortality.

- Compared with T2DM, T1DM was associated with a 9% higher absolute risk of ICU/MV, but no difference in mortality.
- Higher risk of ICU/MV in patients with T1DM than in patients with T2DM was largely accounted for by the presence of DKA.



Diabetes Care 2021;44:1–9 | https://doi.org/10.2337/dc21-0604

Inpatient Hyperglycemia Management and COVID-19

- Inpatient hyperglycemia during this pandemic has been associated with worse outcomes.
- Clinical guidelines recommend maintaining glucose levels between 140 and 180 mg/dL (7.8–10.0 mmol/L) for most critically ill patients
- A target glucose range of 110–180 mg/dL (6.1–10.0 mmol/L) may be appropriate for most critically and noncritically ill patients.
- BG levels; 110_140 mg/dl may be reasonable for stable patients with mild disease without significant hypoglycemia and previous thight glycemic control.
- BG levels > 180 might be acceptable for patients with high risk of hypoglycemia or very labile and critical forms of disease (particularly postprandial continuous tube feeding) and who have limited life expectancy.

Diabetes Ther (2021) 12:121–132

	Glycemic targets	Clinical sit	uation	Insulin regimen	BG monitoring
Critically ill patients	140–180 mg/dL* (7.8–10.0 mmol/ L)	Hemodynamically unstable Parenteral nutrition Unstable insulin requirements Corticosteroid therapy Hemodynamically stable Stable insulin requirements		Continuous intravenous insulin infusion	Every hour
				Subcutaneous insulin Basal-correction or basal-bolus- correction	Every 4–6 h
Noncritically ill patients	110–180 mg/dL** (6.1–10.0 mmol/ L)	T1D T2D on oral agents ± insulin	Not oral intake Oral intake	Basal-correction Basal-bolus- correction	Every 4–6 h ^{##} Before meals and at bedtime ^{##}
		T2D on diet Unknown DM	Glycemia at admission < 180 mg/dL (10.0 mmol/L) Glycemia at admission > 180 mg/dL (10.0 mmol/L)	Correction insulin before meals or every 6 h [#] Basal-bolus- correction	Before meals and at bedtime or every 6 h ^{##} Before meals and at bedtime ^{##}

Table 1 Hyperglycemia management in critically and noncritically ill patients with COVID-19

Inpatient Hyperglycemia Management and COVID-19

Regarding ICU patients, the integration of computer-guided insulin infusion with CGM or further development of new automated insulin delivery systems may be ideal.

A continuous intravenous insulin infusion and scheduled basalbolus correction insulin are the preferred regimens for glycemic control in critically and noncritically ill hospitalized patients, respectively.



	DETAILED TREATMENT GUIDANCE BG 200-250 mg/dL			
1.	NO PRIOR KNOWN DIABETES or KNOWN DIABETES ON <2 ORAL AGENTS	MONITORING		
	 Check HbA_{1c} if none available in last 3 months 	Check BG every 6 h		
а	Start sliding scale regular insulin: moderate to high dose and escalate scale if BG >250 mg/dL			
b	Add scheduled regular insulin every 6 h if TF initiated (see above for regular insulin dosing based on eGFR and hourly TF rate) + scale			
с	Add scheduled regular insulin if BG remains>250 mg/dL + scale even if no TF initiated			
		·		
2.	KNOWN DIABETES PRIOR TO ADMISSION Check BG every 6 h			
	Check HbA _{1c} if none available in last 3 months			
а	T1DM NPO: add basal insulin glargine ASAP (to avoid DKA): use 70% of home dose if eGFR >50 and 50% if eGFR <50 + scale			
b	T1DM on insulin pump and has supplies: if feasible, continue basal insulin via pump (use			
	increased temporary basal rate if needed); rare use in ICU so calculate total basal as in a			
с				
	TF every 6 h (guidance above based on eGFR and TF rate) + scale			
d	T2DM NPO: on regimen that included insulin prior to admission: start 25–50% basal dose + scale			
e	 T2DM on insulin PTA + TF: start 25–50% basal dose and regular insulin for TF coverage every 6 h; see above for dose calculations + scale 			

а	START SLIDING SCALE REGULAR insulin: me	START SLIDING SCALE REGULAR insulin: moderate to high dose scale			
b	ADD SCHEDULED REGULAR INSULIN every	ADD SCHEDULED REGULAR INSULIN every 6 h if uncontrolled with scale or if tube feeds started			
c	ADD BASAL INSULIN GLARGINE for patient	ADD BASAL INSULIN GLARGINE for patients with the following:			
	 T1DM (70% of home dose for eGFR >50 a 	 T1DM (70% of home dose for eGFR >50 and 50% for eGFR <50 to avoid DKA) 			
	 T2DM on home insulin (25–50% basal dos 	 T2DM on home insulin (25–50% basal dose) or >2 drugs 			
	 Uncontrolled glucose on regular insulin a 	 Uncontrolled glucose on regular insulin alone: use 0.1–0.3 units/kg daily (below) 			
	 NPH may be appropriate basal for patient 	 NPH may be appropriate basal for patients on steroids 			
BG 250–350 m	ng/dL: START SCHEDULED SUBCUTANEOUS INSUL	IN			
		HIGH SENSITIVITY	MODERATE SENSITIVITY	LOW SENSITIVITY	
		No known diabetes,	Known DM, renal	Known DM, renal	
		known DM with renal	failure (eGFR 30–50),	function (eGFR >50),	
		failure (eGFR<30), insulin	intermediate disease	steroids, severe	
		naive, mild disease*	course**	disease***	
Type of insulin			Insulin dose (units/kg)		
BASAL#	Glargine daily: noon or 6 P.M.	0.1 units/kg/day	0.15–0.2 units/kg/day	0.3 units/kg/day	
BOLUS	Scheduled regular insulin every 6 h	Approximate start doses (Approximate start doses (units/kg every 6 h); use clinical judgement		
	No tube feeds	0.1	0.15	0.2	
	Low rate tube feeds (≤25 cc/h)	0.1-0.125	0.1-0.15	0.2-0.25	
	High rate tube feeds (≥25 cc/h)	0.15	0.2	0.3	
SCALE	Regular insulin every 6 h	Moderate	Moderate	High	

Basal-bolus insulin regimen

insulin should be initiated at a dose of 0.4 units/kg/day.

- consider lower starting dose of 0.2 units/kg/day in elderly patients or those with liver or renal dysfunction.
- The initial dose can be higher, (e.g., 0.6 units/kg/day) in overweight/obese patients, or those who had a high pill burden before admission.
- A achieve and maintain pre-meal glucose values of <140 mg/dl and post-meal glucose values of <180 mg/dl</p>


Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 407e413



The infusion should be initiated at a low dose of 0.05_0.10 units/kg/hour, and the infusion rate should be titrated taking into account several factors.

Once glucose ranges were within 200–300 mg/dL at lower hourly insulin drip rates, we would transition to subcutaneous insulin as soon as possible given the extenuating health care considerations described above.





Manage hyperglycemia in patients on glucocorticoids

- Even patients who have previously well-controlled blood glucose levels may require large doses of insulin (e.g., >2 units/kg/day) to achieve glycemic control following initiation of glucocorticoids.
- For patients receiving twice daily intermediate acting glucocorticoids (e.g., methylprednisolone), it is best to start a basal bolus insulin regimen.
- For patients receiving once a day morning dose of prednisolone: Basal (NPH) in morning and /or Bolus (regular) at lunch for support high blood glucose values in the afternoon and evening hours.
- uncontrolled hyperglycemia despite the use of basal-bolus regimen, the use of intravenous insulin infusion should be considered.



Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15 (2021) 407e413

Management of patients T2DM

Prescribe oral glucose lowering agents	No traindications for it Mild Covid	Mild Hyperglycemia (Pre-meal < 180 mg/dl) (Post-meal < 250 mg/dl)
Relatively Safe	Caution	Stop
DPP-4 inhibitors	Metformin Risk of lactic acidosis if moderately to severely ill with hemodynamic instability or hypoxia	SGLT-2 Inhibitors Increase risk of dehydration and euglycemic ketoacidosis
Vildagliptin/Teneligliptin (Low cost) Sitagliptin/Linagliptin (High cost)	Sulfonylureas Risk of hypoglycemia if oral intake is poor or with concomitant use of HCQS, and/or insulin therapy	Pioglitazone Risk of fluid retention and edema; contraindicated in cardiac or hepatic dysfunction





The Management of patients with TIDM During Surgery



Insulin pump therapy

- in patients on insulin pump therapy who are undergoing short procedures, the CSII can be continued at the usual or slightly reduced overnight basal rate.
- Insulin pump-treated patients can also be maintained on CSII for major procedures, as long as the integrity of the infusion and infusion site is ensured.
- hyperglycemia can be corrected using the standard home ISF



IV Insulin drip during surgery

- IV insulin is typically started at a dose of 0.03 units/kg/hour for patients who are euglycemic at the time of surgery.
- For elective surgeries; 1 unit of regular insulin is infused intravenously for each 4 to 6 g of administered glucose.
- For surgical emergencies: 1 unit of regular insulin for every 2 to 4 g of exogenous glucose
- Concentrations of 120 to 150 mg/dL should be the goal.
- Glycemic and metabolic goals for surgery (ISPAD) in a range of 5 10 mmol/l (90 180 mg/dl)



Rate of insulin administration

Table 583-9 GUIDELINES FOR INTRAVENOUS INSULIN COVERAGE

DURING SURGERY

BLOOD GLUCOSE LEVEL (mg/dL)	INSULIN INFUSION (U/kg/hr)	BLOOD GLUCOSE MONITORING
<120	0.00	1 hr
121-200	0.03	2 hr
200-300	0.06	2 hr
300-400	0.08	1 hr [†]
400	0.10	1 hr [†]

Fluid therapy during surgery

- An infusion of 5% glucose and 0.45% or 0.9% saline solution with 20 mEq/L of potassium acetate is given at 1.5 times maintenance rate.
- If BG <70 mg/dl give bolus of IV 10% Dextrose 1-2ml/kg; recheck BG 15 minutes later and repeat if necessary.
- If still 70 mg/dl, stop IV insulin for 15 min and recheck and discuss with diabetes team.



Thank you

